DOT1L and ovarian serous adenocarcinoma: In order to evaluate the therapeutic effects of DOT1L inhibitors on a larger ovarian cancer cell line panel in vitro, we chose OV90 and CaOV3, which could represent high-grade serous ovarian cancer for CCK8 and colony formation assay [33].